Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720350 | 0.78 | EPHX1 (0.34) | LMNAEPHX1 | |
| SCHEMBL28564561 | 0.76 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2EPHX1 | |
| SCHEMBL21318034 | 0.73 | LMNA (0.39) | LMNAPOLBTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL14720687 | 0.72 | SMN1; SMN2 (0.42) | LMNAPOLBMAPTSMN1; SMN2 | |
| SCHEMBL3998210 | 0.71 | MAPT (0.33) | LMNAMAPT | |
| SCHEMBL25773481 | 0.70 | EPHX1 (0.34) | EPHX1 | |
| SCHEMBL18678807 | 0.69 | NFKB1 (0.39) | LMNAPOLBMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL23811147 | 0.68 | PPM1B (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL13224367 | 0.68 | MAPT (0.38) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL8447826 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686348-B2 | N-HYDROXY-6-((2-(4-PYRIDYL)-1-BENZOFURAN-5-YL)SULPHONYL)-4,5,6,7 -TETRAHYDRO(2,3-C)-PYRIDINE-5-CARBOXAMIDE FOR EXAMPLE; TREATING RHEUMATIC DISEASES, CANCER | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20020137744-A1 | Metalloprotease inhibitors | LES LABORATOIRES SERVIER (FR) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137744-A1 | Metalloprotease inhibitors | MMP9, MMP3, MMP2 | LMNA 2480/4885POLB 1235/4885MAPT 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.